secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001193125-25-120329
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha secures FDA alignment on TSHA-102 pivotal trial design; Q1 net loss $21.5M
--------------------------------------------------------------------------------

- FDA alignment on pivotal Part B trial design; IND amendment with protocol/SAP expected Q2 2025, potentially expediting registration.
- TSHA-102 well tolerated: no treatment-related SAEs or DLTs in 10 patients (6 high dose, 4 low dose) as of April 10, 2025 cutoff.
- Q1 2025 net loss $21.5M ($0.08/sh) vs $24.1M ($0.10/sh) in Q1 2024; cash $116.6M expected into Q4 2026.
- R&D expenses $15.6M, down from $20.7M YoY due to lower manufacturing costs; G&A expenses $8.2M, up from $7.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525120329/0001193125-25-120329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525120329/d89129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-120329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer